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The impact of bone marrow (BM) GD2-positive cells on survival has been evaluated in 145 Italian children with localised
neuroblastoma (NB) evaluated at diagnosis by anti-GD2 immunocytochemistry. Nineteen of these (13.1%) were found to be BM
GD2-positive, with the number of positive cells ranging between 1 and 155 out of 1 10
6 total cells analysed. Seven/19 (38.8%)
GD2-positive vs 12/126 (9.5%) GD2-negative patients relapsed. The 5-year event-free survival (EFS) and overall survival of the GD2-
positive patients was significantly worse than that of the GD2-negative ones (62.2 vs 89.9%, Po0.001; and 74.9 vs 95.9%, P¼0.005,
respectively). GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion.
Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children
positive for either one of these two markers (EFS¼96.9 vs 66.0%, Po0.001). In conclusion, GD2 positivity may represent a
prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations
might help identifying patients that require a more careful follow-up.
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Neuroblastoma (NB) is the most common extracranial solid
malignancy of childhood (Henry et al, 2005). Staging, clinical
management and prognosis mainly depend on the presence/
absence of bone marrow (BM) and skeletal involvement (Brodeur
et al, 1993). Almost 50% of NB patients present at diagnosis with
localised disease, that is, they do not have evidence of BM
metastases, as assessed by morphological examination of both
marrow smears and trephine biopsies, nor other distant localisa-
tions investigated by
123I-MIBG scintigraphy.
Usually patients with localised disease are treated by surgery
alone (stage 1 and 2) or by standard-dose chemotherapy followed
by surgery (stage 3), unless amplification of the Myc-N proto-
oncogene is detected in their tumour cells (Rubie et al, 1997b;
Haase et al, 1999; Simon et al, 2004; Henry et al, 2005; Maris,
2005), which requires a more aggressive chemotherapeutic regi-
men. Event-free (EFS) and overall (OS) survival of the patients
with localised disease without Myc-N amplification are good (95%
for stage 1, 86% stage 2 and 65% for stage 3 patients; Cotterill et al,
2000), but a small percentage of them relapse and may die of
disease.
Genetic abnormalities at chromosome 1p (Rubie et al, 1997a),
3p, 11q (Spitz et al, 2003; Attiyeh et al, 2005; Simon et al, 2006) and
17q (Brinkschmidt et al, 2001), as well as biochemical (Simon et al,
2003), histological (Perez et al, 2000; Navarro et al, 2006; Sano
et al, 2006), and biological factors (Christiansen et al, 1995;
Cheung et al, 1997; Kramer et al, 1997; Perez et al, 2000;
Ladenstein et al, 2001; Mora et al, 2001; Krams et al, 2003; Riley
et al, 2004; Haber et al, 2006; Spitz et al, 2006), do not seem to have
the same relevance in patients with localised NB as they do in
patients with metastatic disease. Gene expression profiling and
GCH studies have suggested specific favourable and unfavourable
NB signatures (Takita et al, 2004; Ohira et al, 2005; Vandesompele
et al, 2005), but presently a widespread identification of patients at
risk of relapse by these techniques cannot be envisaged. Therefore,
an independent, easily applicable, prognostic marker able to
identify patients that would benefit from a more careful follow-up
is currently lacking.
In a previous study, aimed to assess the diagnostic and
prognostic role of different techniques detection of NB tumour
cells in peripheral blood and BM, we observed that in patients with
localised NB the GD2 positivity in BM was negatively associated
with survival (Corrias et al, 2004). However, this finding was based
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son a small sample size with a relatively short follow-up. The aim of
the present investigation was to evaluate the impact of BM GD2
positivity, evaluated at diagnosis by anti-GD2 immunocytochem-
istry (IC), and its combined effect with other known risk factors on
survival of a larger cohort of patients with localised NB.
MATERIALS AND METHODS
Patients
One hundred and forty-five consecutive NB patients, diagnosed
with localised disease (stages 1–3) according to INSS criteria
(Brodeur et al, 1993) at 20 Italian paediatric oncology centres
between January 1997 and June 2003, with available information
on BM GD2 status at diagnosis, were included in the study. Disease
staging (Brodeur et al, 1993) at diagnosis, including appropriate
imaging,
123I MIBG scintigraphy and BM evaluation, was made at
the referring oncology centre and centrally reviewed at the Gaslini
Institute.
Therapeutic approach for stage 1–2 patients included only
surgery followed by a complete re-evaluation with appropriate
imaging 1 month later. Stage 3 patients also received chemotherapy
according to national or international protocols. Stage 3 and 2
Myc-N-amplified patients received high-dose chemotherapy, mye-
loablative therapy with haematopoietic stem cell rescue and local
radiotherapy. In case of relapse, a complete restaging, including
imaging and BM evaluation, was performed.
For each patient, demographic, clinical and follow-up data,
together with information on biological characteristics and other
prognostic risk factors as serum LDH, NSE and ferritin, tumour
Myc-N amplification and 1p status (Ambros et al, 2003), are
summarised in Table 1. Data were retrieved from the Italian
Neuroblastoma Registry (INBR) that collects information on
clinical and biological characteristics of patients at diagnosis as
treatment; follow-up is sought during protocol administration and
then at least yearly after treatment discontinuation (Conte et al,
2006). Pathology data regarding the primary tumour were not
considered for this study, since information according to the
criteria proposed by the International Neuroblastoma Pathology
Committee (INPC) was not available for patients diagnosed before
2003.
BM analysis
In general, BM aspirations and bone trephine biopsies at both iliac
crests were performed under general anaesthesia during surgical
procedure on the primary tumour or during ‘ad hoc’ sedation. For
morphological analysis, three May Gru ¨nwald–Giemsa-stained
slides from each site were examined by an experienced cytomor-
phologist and centrally reviewed. Trephine biopsies were obtained
by a Jamshidi needle, and only biopsies containing at least 5mm
3
of tissue were considered adequate for evaluation. At least 30 high-
resolution fields of haematoxylin–eosin-stained sections were
evaluated by an experienced pathologist and centrally reviewed.
For the purpose of this study, GD2-IC was centrally performed
at the Italian NB reference laboratory, as previously described
(Corrias et al, 2004). Briefly, six cytospins, each containing 5 10
5
mononuclear cells, were fixed in cold acetone and incubated with
the 3F8 anti-GD2 mAb (kindly donated by Dr Nai-Kong Cheung,
Memorial Sloan Kettering Cancer Center, New York, NY, USA).
After washing, slides were incubated with a biotinylated anti-
mouse antibody and developed with an avidin–alkaline phospha-
tase conjugate (DAKO, Copenhagen, Denmark). Enumeration of
GD2-positive cells was based on both morphological and
immunological criteria, according to standardised conditions
(Swerts et al, 2005). Namely, the presence of round nuclei larger
than that of small lymphocytes, granular chromatic structure and
scarce amount of cytoplasm were considered positive morpholo-
gical criteria; strong red staining localised to the entire cell
membrane and cytoplasm was the positive immunological
criterion. Bone marrow samples were considered positive if at
least three positive tumour cells were detected out of the 3 10
6
cells analysed.
The study was approved by the Institutions’ Ethical Committees.
All analyses were performed after informed consent was given
from the patients themselves or their legal guardians, according to
the Helsinki declaration.
Statistical analysis
Descriptive statistics were reported as percentages for categorical
variables. For continuous and counting data, medians with
interquartile range (IQR) were used due to the non-normal
distribution of the observations and to reduce the effect of outliers.
Table 1 Demographic, clinical, biochemical and genetic features of the
145 patients with localised NB stratified by GD2 status
GD2 negative
(n¼126)
GD2 positive
(n¼19)
Total
(n¼145)
n % n % Pn%
Gender 0.059
Male 69 54.8 6 31.6 75 51.7
Female 57 45.2 13 68.4 70 48.3
Age 0.932
o12 months 61 48.4 9 47.4 70 48.3
X12 months 65 51.6 10 52.6 75 51.7
Primary site 0.923
Neck 7 5.6 0 0.0 7 4.8
Thorax 29 23.0 4 21.1 33 22.8
Abdomen,
adrenal
44 34.9 7 36.8 51 35.2
Abdomen, other
sites
46 36.5 8 42.1 54 37.2
INSS stage 0.315
Stage 1 59 46.8 7 36.8 66 45.5
Stage 2 35 27.8 4 21.1 39 26.9
Stage 3 32 25.4 8 42.1 40 27.6
NSE (78 tested) 0.660
o100ngml
 1 57 89.1 12 85.7 69 88.5
X100ngml
 1 7 10.9 2 14.3 9 11.5
LDH (123 tested) 0.999
o1000IUml
 1 86 81.9 15 83.3 101 82.1
X1000IUml
 1 19 18.1 3 16.7 22 17.9
Ferritin (95 tested) 0.999
o150ngml
 1 63 77.8 11 78.6 74 77.9
X150ngml
 1 18 22.2 3 21.4 21 22.1
Myc-N (124 tested) 0.999
Not amplified 95 88.8 15 88.2 110 88.7
Amplified 12 11.2 2 11.8 14 11.3
1p36 (105 tested) 0.999
Not deleted 60 67.4 11 68.8 71 67.6
Deleted 14 15.7 2 12.5 16 15.2
Imbalance 15 16.9 3 18.8 18 17.1
5-year EFS 126 89.9 19 62.2 o0.001
5-year OS 126 95.9 19 74.9 0.005
EFS¼event-free survival; NB¼neuroblastoma; OS¼overall survival.
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sPatients were stratified according to their BM GD2 status and
comparisons of frequency data were performed by means of the
w
2-test or the Fisher’s exact test, when appropriate. The Wilcoxon
Mann–Whitney test was used to compare median values, while the
Spearman r coefficient was used to assess correlation between
variables. Event-free survival and OS analyses were performed
according to the Kaplan–Meier method and compared by the log-
rank test. A P-value o0.05 was considered as statistically
significant. Analyses were performed using Stata for Windows
statistical package (release 7.0; Stata Corporation, College Station,
TX, USA).
RESULTS
During the study period, 145 patients diagnosed with localised
NB and registered in the INBR had their BM aspirates analysed
at diagnosis by anti-GD2-IC. Patients included in the study were
similar for age, sex, stage, Myc-N status and survival to the
children with localised NB without information on GD2 status at
diagnosis (see Supplementary data).
Demographic, clinical, biochemical and genetic features of the
145 study patients stratified according to BM GD2-IC status are
reported in Table 1. In more detail, 126 patients (86.9%) were GD2
negative and 19 (13.1%) were GD2 positive. Among the 19 GD2-
positive patients (Table 2), the number of positive cells ranged
between 1 and 155 (median¼3; IQR 2-20) out of 10
6 total cells
examined. It is to be noted that of the 11 patients with less than
five GD2-positive cells/10
6 total cells, seven were also evaluated by
RT-PCR and all but one were found to be positive for at least one
NB molecular marker (data not shown). Three examples of GD2-
positive samples are shown in Figure 1. As reported in Table 1, no
association was found between GD2 status and each of the other
risk factors considered.
Seven (36.8%) of the 19 GD2-positive patients relapsed, all
locally, and four of them died due to local disease progression
(Table 2). The 5-year EFS and OS of this group were 62.2 and
74.9%, respectively (Table 1; Figure 2A and B). In these patients, an
inverse correlation between the number of GD2-positive cells and
the time to relapse was observed (r¼  0.786, P¼0.036).
Conversely, among the 126 BM GD2-negative patients, only 12
(9.5%) relapsed, 10 locally and two with metastatic disease, and
five subsequently died (Table 2) with a 5-year EFS of 89.9% and an
OS of 95.9% (Table 1; Figure 2A and B). Differences in EFS and OS
between the two groups were significant (Po0.001 and P¼0.005,
respectively; Table 1). If, as in our previous study, the five cells/10
6
cut off was used to discriminate positive BM samples, differences
in survival remained highly significant (data not shown). Table 3
further reports on the 5-year EFS analyses on the entire cohort also
considering other clinical and biological risk factors. A statistically
significant worse effect was observed for unresectable disease (i.e.,
stage 3) (EFS¼76.7%) vs resectable disease (i.e., stage 1–2)
(EFS¼89.8%; P¼0.033), high LDH levels (72.1 vs 89.5%,
P¼0.010), Myc-N amplification (EFS¼57.1 vs 90.4%, Po0.001)
Table 2 Features of the GD2-positive patients and of the GD2-negative patients who relapsed
Stage
Sex/age
(months)
GD2+ cells/10
6
total Tumour site
LDH
(IUml
 1) Myc-N 1p
Relapse
(months)
Type of
relapse Follow-up
a
1 M/45 1.3 Thorax 650 Normal Normal — — CR
1 F/2 1.0 Abdomen 475 Normal Normal — — CR
1 M/25 2.2 Pelvis 523 Normal Normal — — CR
1 F/93 1.6 Thorax 601 Normal Normal — — CR
1 F/2 3.0 Abdomen 411 ND ND — — CR
1 M/2 10.0 Abdomen 494 Normal Normal — — CR
1 M/6 39.3 Abdomen 1961 Amplified Deleted 1.8 Local DPD
1 F/10 Negative Abdomen 1693 Amplified Deleted 1.4 Local+Met DPD
1 F/25 Negative Thorax 617 ND ND 18.0 Local AWD
1 F/1 Negative Abdomen NE Normal Normal 10.0 Local+Met AWD
2 F/59 8.0 Abdomen 339 Normal ND — — CR
2 F/3 2.0 Abdomen 336 Normal Imbalance — — CR
2 F/10 2.0 Abdomen 484 Gain Normal 24.0 Local DPD
2 F/6 3.3 Abdomen 949 Normal Normal 15.0 Local CR
2 F/43 Negative Abdomen NE Normal Deleted 30.0 Local CR
2 M/7 Negative Abdomen 1481 Normal ND 3.8 Local CR
2 F/11 Negative Neck 444 Normal Imbalance 25.1 Local AWD
2 M/1 Negative Abdomen 409 Normal Deleted 5.0 Local DPD
3 M/15 2.0 Thorax 477 Normal Imbalance — — CR
3 F/50 4.5 Abdomen 735 Normal Deleted — — CR
3 F/15 5.0 Abdomen 1051 Normal Normal — — CR
3 F/6 20.0 Abdomen 791 Normal Normal — — CR
3 F/8 34.6 Abdomen 437 Normal Normal 8.1 Local CR
3 F/31 29.1 Abdomen 2445 Amplified ND 13.3 Local DPD
3 F/18 155.0 Abdomen ND Normal Normal 1 Local DPD
3 M/73 1.0 Thor/Abd 800 ND Imbalance 13.2 Local CR
3 F/11 Negative Abdomen 6247 Amplified Deleted 7.0 Local DPD
3 F/118 Negative Abdomen 127 ND Imbalance 7.0 Local AWD
3 M/17 Negative Abdomen 4672 Amplified Deleted 1.0 Local DPD
3 M/13 Negative Neck 536 Amplified Deleted 14.0 Local DPD
3 M/7 Negative Abdomen 401 Normal Deleted 17.0 Local CR
aAWD¼alive with disease; CR¼complete remission; DPD¼dead of progressive disease; F¼female; M¼male; ND¼not determined.
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sand chromosome 1p status (EFS¼45.8% for deletion, 83% for
imbalance and 92.7% for normal, Po0.001). The negative effect of
1p deletion remained even if 1p imbalance was pooled with the not
deleted cases (data not shown); for this reason, in subsequent
analyses patients with 1p imbalance were grouped with the not
deleted ones.
Since Myc-N status directs patients towards either standard or
high-risk treatment, survival analysis was repeated in patients with
Figure 1 Cytospin of BM aspirates fixed in acetone and immunologically stained with anti-GD2 antibody. (A, B) Rosettes of NB cells stained in red, from
patients F/18 and F/8, respectively; (C) a single NB cell stained in red from patient M/73; (D) a completely negative aspirate. Magnification is  40.
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Figure 2 (A) Event-free survival of patients with localised NB stratified by BM GD2-IC status. (B) Overall survival of patients with localised NB stratified
by GD2-IC status. (C) Event-free survival of patients with normal Myc-N status stratified by GD2-IC status. (D) Event-free survival of patients with normal
Myc-N status stratified by GD2-IC and chromosome 1p status.
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sand without Myc-N amplification. In Myc-N-amplified patients,
GD2 negativity was associated with a better survival (EFS 66 vs
0%), but the difference was not significant (P¼0.073), likely due to
the small number of cases. However, in Myc-N non-amplified
patients, the BM GD2 negativity was associated with a significantly
better outcome (EFS¼93.2 vs 72.7%, P¼0.008; Figure 2C). In the
same Myc-N-negative patients, the combined prognostic role of
GD2 and 1p status was also assessed. Patients negative for both
markers had a 96.9% EFS, which was significantly better than that
observed among children positive for at least one marker
(EFS¼66.0%; Po0.001; Figure 2D). In the same group of Myc-
N-negative patients, the OS showed a similar pattern (98% for the
GD2-negative subjects vs 83% for the GD2-positive subjects).
Finally the OS of patients positive for either GD2 or Myc-N was
worse than that of patients negative for both the markers (83.1 vs
100%), but the very low number of observed deaths prevents one
to draw definitive conclusions.
Finally, among BM GD2-IC-positive patients, a worse survival
was found in children with X20 GD2-positive cells/10
6 total cells,
corresponding to the fourth quartile (EFS¼77.1 vs 20.0%,
P¼0.002). A similar result was also observed after excluding the
two patients with Myc-N amplification (data not shown).
Because of the small sample size (19 BM GD2-positive patients)
and low number of events, results from a multivariate analysis
should be taken with caution and are herewith reported only as
Supplementary data. In this analysis, the GD2-IC status seemed to
maintain its prognostic role independently from both Myc-N
amplification and 1p deletion. It is of note that conversely Myc-N
amplification and 1p deletion were indeed correlated, being 72.7%
of Myc-N amplified patients also deleted of 1P.
DISCUSSION
This study has confirmed our previous observation (Corrias et al,
2004) of a negative impact of BM GD2-positive cell infiltration on
survival of patients with localised NB. In particular, in this larger
cohort of patients with a longer follow-up, we have shown that this
effect is not due to the association with other risk factors as Myc-N
amplification and 1p deletion.
Other reports have previously documented that tumour cells
may be detected by IC and/or RT-PCR in BM of children with
localised NB (Moss et al, 1991; Cheung et al, 1998; Trager et al,
2003; Corrias et al, 2004; Simon et al, 2004; Ifversen et al, 2005;
Russell et al, 2005; Swerts et al, 2006). However, the limited
number of patients analysed and/or the short follow-up of those
studies did not allow one to draw definitive conclusions on the
prognostic impact of this detection. In addition, a large multi-
centre European study (Navarro et al, 2006) and several other
national studies (Christiansen et al, 1995; Cheung et al, 1997;
Ladenstein et al, 2001; Simon et al, 2003; Sano et al, 2006;
Spitz et al, 2006) have indicated that stage and Myc-N status
were the only independent risk factors for children with localised
NB. However, Myc-N amplification is a relatively rare event,
occurring, as in our series, in about 10% of localised NB patients
(Haase et al, 1999; Perez et al, 2000; Henry et al, 2005; Maris, 2005)
and is thus inadequate to identify all the patients who will
eventually relapse.
A negative prognostic role of unfavourable histology (Perez
et al, 2000), of 11q LOH (Attiyeh et al, 2005; Simon et al, 2006),
and of a specific GCH profile (Schleiermacher et al, 2007), was also
previously reported in patients with localised disease. This effect
was independent from Myc-N status. Unfortunately, homogeneous
information on tumour histology (i.e., INPC classification) was not
available in our registry because of the long recruitment period
covered by this study. Moreover, our patients were not screened
for genetic abnormalities other than Myc-N amplification and 1p
deletion. Even if genetic screening could have been more precise,
our observation of a negative prognostic role of BM GD2-IC
positivity suggests that also this technique, which has become
accurate, thanks to recent standardisation (Swerts et al, 2005),
might be of interest in future studies.
The low relapse rate observed in our cohort is similar to that
expected in patients with localised NB, and indicates that staging
was correct. The fact that presence of GD2-positive cells in the BM
correlated with a higher tendency of relapse at the primary site,
instead that in the BM, is surprising. However, also Perez et al
(2000) did not observe further BM involvement in eight stage 1–2
patients found positive by BM immunocytology. Thus, it is
conceivable that the very few GD2-positive cells, detected by IC
at diagnosis, were unable to survive and actively proliferate in the
BM. Whether this inability to invade the marrow compartment was
related to the NB cells themselves or to the presence/absence of
factors in the BM microenvironment (Fidler, 2003) remains to be
determined in future studies.
Our observation that higher number of GD2-positive cells
correlated with poorest survival and with a shorter time to relapse
is similar to that previously reported by Moss et al (1991). Even
if this finding was based on a very small sample size (i.e., seven
relapses in GD2-positive patients), it suggests that quantification
Table 3 EFS of patients with localised NB stratified according to the
indicated variables
Variables n 5-year EFS % s.e.
a P
GD2 o0.001
Negative 126 89.9 0.03
Positive 19 62.2 0.36
Gender 0.166
Male 70 90.5 0.03
Female 75 81.2 0.05
Age 0.352
o12 months 70 83.6 0.05
X12 months 75 88.7 0.04
Primary site
b 0.211
Abdomen 105 84.1 0.04
Thorax 40 91.6 0.05
Tumour stage (INSS) 0.033
Stages 1–2 105 89.8 0.03
Stage 3 40 76.7 0.07
NSE (78 tested) 0.445
o100ngml
 1 69 86.1 0.04
X100ngml
 1 9 77.8 0.14
LDH (123 tested) 0.010
o1000IUml
 1 101 89.5 0.03
X1000IUml
 1 22 72.1 0.10
Ferritin (95 tested) 0.604
o150ngml
 1 74 84.4 0.04
X150ngml
 1 21 80.0 0.09
Myc-N (124 tested) o0.001
Not amplified 110 90.4 0.03
Amplified 14 57.1 0.13
o0.001
1p36 (105 tested)
Not deleted 71 92.7 0.03
Deleted 16 45.8 0.14
Imbalance 18 83.0 0.09
EFS¼event-free survival; NB¼neuroblastoma.
aStandard error.
bAbdomen¼
adrenal+other abdominal site; thorax¼thorax+neck.
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sby IC might add useful clinical information and that BM GD2-IC
positivity reflects a biological feature of the neuroblasts that can
affect the disease course.
In our study, survival analysis on other prognostic factors
confirmed the negative role of Myc-N amplification, high LDH
serum levels and 1p deletion. Only a multivariable analysis based
on a larger series will be able to assess the combined effect of BM
GD2 positivity and the other known major risk factors. However,
our data suggest that in patients with localised disease without
Myc-N amplification, the combination of BM GD2-IC and 1p status
might help individuating those at risk of relapse.
In conclusion, we believe that BM GD2-IC analysis might have
the potential to discriminate different risk groups within localised
NB patients. In fact, GD2-IC seems to provide additional
information on biological features and has the advantage of
generating quantitative data. We neither recommend that BM
GD2-IC status be used for staging purposes, nor the patient be
shifted to a more intensive treatment because not all the GD2
positive patients relapsed. However, in future multi-national
studies, patients with localised disease should be evaluated by
GD2-IC. In fact, in the presence of BM GD2-positive cells,
especially if combined with chromosome 1p deletion, patients
should be closely followed, and in case of relapse, they should be
treated more aggressively.
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